Latest news - Johnson & Johnson
Oct 10, 2024 · A collection of stories that highlight the way Johnson & Johnson is making an impact in the lives of its consumers, and the latest press releases from the company.
Press Releases - Johnson & Johnson
Dec 26, 2024 · Explore all Johnson & Johnson published press releases by date and/or topic of news.
News | Johnson & Johnson - Investors
You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact us with any questions or search this site for more information.
5 facts about Johnson & Johnson’s investigational Janssen COVID …
Jul 30, 2020 · 5 facts about Johnson & Johnson’s investigational Janssen COVID-19 vaccine candidate With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine ...
NEW BRUNSWICK, N.J., January 6, 2022 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against ...
Media Center - Johnson & Johnson
Read the latest press releases from Johnson & Johnson, find our press contacts and see our latest social media posts.
Johnson & Johnson Announces Real-World Evidence and Phase 3 …
Sep 21, 2021 · Johnson & Johnson single-shot vaccine showed strong and long-lasting protection in the real world The largest real-world evidence study for a COVID-19 vaccine reported to date in the U.S. demonstrated stable vaccine effectiveness of 79 percent (CI, 77%-80%) for COVID-19-related infections and 81 percent (CI, 79%-84%) for COVID-19-related ...
Johnson & Johnson Reports Q3 2024 Results | Johnson & Johnson
Oct 15, 2024 · NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer.
Johnson & Johnson Announces Plans to Accelerate Innovation, …
Nov 12, 2021 · Johnson & Johnson would Remain a Global Leader in Healthcare, Focused on Major Unmet Medical Needs and Materially Advancing Standard of Care through Biopharmaceutical and Medical Device Innovation and Technology
Johnson & Johnson advances leadership in rheumatic disease …
Nov 7, 2024 · Johnson Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 Annual Meeting.